Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment

Anti-Cancer Drugs

Volumn 22, Issue 10, 2011, Pages 1030-1033

  Aigner, Julia ^a   Bischofs, Esther ^a   Hallscheidt, Peter ^a   Sohn, Christof ^a   Schneeweiss, Andreas ^a   Eichbaum, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

advanced epithelial ovarian cancer; angiogenesis; bevacizumab; low dose cyclophosphamide

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; RANITIDINE; TOPOTECAN;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; ARTICLE; ASCITES; CANCER RECURRENCE; CANCER STAGING; CARCINOMATOUS PERITONITIS; CASE REPORT; DIAGNOSTIC IMAGING; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LAPAROTOMY; LONG TERM CARE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PLEURA METASTASIS; PLEURODESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT FAILURE;

ADMINISTRATION, METRONOMIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 80053641617     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834a62b4     Document Type: Article

References (18)

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676. (Pubitemid 36749215)
3. Sandler AB, Gray R, Bhramer J. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial-E4599. ASCO 2005 Abstract LBA4.
4. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28:2144-2150.
5. Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003; 3:421-422. (Pubitemid 36395551)
6. Burger RA, Sill M, Monk BJ, Greer BE, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG). J Clin Oncol 2007; 25:5165-5171. (Pubitemid 350237599)
7. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritonela serous cancer. J Clin Oncol 2007; 25: 5180-5186. (Pubitemid 350232248)
8. Mcha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal and fallopian tube cancer. Int J Gynecol Cancer 2007; 17:771-776. (Pubitemid 47063333)
9. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105:1045-1047. (Pubitemid 30217688)
10. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003; 100:12917-12922. (Pubitemid 37340000)
11. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002; 62: 2731-2735. (Pubitemid 34525751)
12. Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007; 107: 326-330. (Pubitemid 47575735)
13. Sanchez-Munoz A, Jurado JM, Perez-Ruiz E, Alba E. Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pretreated ovarian cancer. Clin Transl Oncol 2009; 11: 329-331.
14. Mano MS, Awada A, Minisini A, Atalay G, Lago LD, Cardoso F, Piccart M. Remaining controversis in the upfront management of advanced ovarian cancer. Int J Gynecol Cancer 2004; 14:707-720. (Pubitemid 39238154)
15. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF) based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006; 102:140-144. (Pubitemid 44056265)
16. Garcia AA, Oza AM, Hirte H. Interim report of a phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian and primary peritoneal carcinoma: a Trial of the California, Chicago and Princess Margaret Hospital phase II Consortia. Clin Oncol 2008; 26:76-82.
17. Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, Fowler J, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010; 28:18.
18. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia A, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophophamide and bevacizumab. Clin Cancer Res 2008; 14: 7554-7563.